Loading stock data…
Biodesix, Inc. (BDSX)
$26.63+0.45 (+1.72%)
Market ClosedLast close Sep 8
Biodesix, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Biodesix, Inc. in the Healthcare sector is trading at $26.63 with a market capitalization of $167M. Wall Street consensus targets $34.00 (6 analysts), implying a +27.7% move over the next 12 months. The stock is currently near its 52-week high of $31.31, remaining 76.7% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +27.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $25.55M↓ | $28.75M↑ | $21.77M↑ | $20.02M↑ | $17.96M |
| Gross Profit | $21.35M↓ | $23.88M↑ | $17.66M↑ | $15.99M↑ | $14.26M |
| Operating Income | -$6.20M↓ | -$1.97M↑ | -$7.04M↑ | -$9.69M↓ | -$9.06M |
| Net Income | -$7.79M↓ | -$3.98M↑ | -$8.72M↑ | -$11.47M↓ | -$11.10M |
Peer Comparison
JNJUNHPFE
Fundamentals
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$166.73M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.42
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-349.95%
Volume
Today's trading volume
86,406
Recent News
What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now?
Does Biodesix, Inc. (BDSX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High?
The consensus price target hints at a 26.7% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.
Biodesix (BDSX) Q2 2026 Earnings Call Transcript
Revenue jumped 34% as diagnostic testing surged on primary care adoption gains.
Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference
Biodesix (NASDAQ:BDSX) said its commercial expansion, broader primary care outreach and recently published clinical data supporting use of its Nodify CDT test in smaller lung nodules are among the principal drivers of its growth strategy. Speaking at the Canaccord Genuity Growth Conference, Chief E